Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12013920 | 0.84 | SIGMAR1 (0.70) | SIGMAR1KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL28801570 | 0.84 | SIGMAR1 (0.70) | SIGMAR1KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL8825661 | 0.84 | SIGMAR1 (0.62) | SIGMAR1KDM4EALDH1A1MAPTHTR1A | |
| SCHEMBL28186295 | 0.83 | SIGMAR1 (0.90) | SIGMAR1KDM4EALDH1A1MAPTHTR1A | |
| SCHEMBL20804357 | 0.83 | SIGMAR1 (0.90) | SIGMAR1KDM4EALDH1A1MAPTHTR1A | |
| SCHEMBL6943757 | 0.83 | SIGMAR1 (0.68) | SIGMAR1KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL22829113 | 0.83 | SIGMAR1 (0.68) | SIGMAR1KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL621695 | 0.82 | HRH3 (0.62) | SIGMAR1ACHE | |
| Hydrochloric Acid SCHEMBL11535920 | 0.82 | SIGMAR1 (0.67) | SIGMAR1KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL14492265 | 0.81 | CXCR4 (0.62) | KDM4EALDH1A1MAPTDRD4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484879-B1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2020-12-30 | — | — | EP | disclosed |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-02-05 | — | — | US | disclosed |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| WO-2018011090-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | WO | disclosed |
| WO-2002006272-A1 | POLYFLUOROALKYLTRIAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-01-24 | — | — | WO | disclosed |
| EP-1150972-A1 | TRIAZOLE AND TETRAZOLE DERIVATIVES, AND THEIR THERAPEUTIC USE | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001064671-A2 | HALOIMIDAZOLE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 AND SEROTONINERGIC 5-HT4 RECEPTORS | SANOFI-SYNTHELABO (FR) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064631-A2 | DERIVES DE POLYFLUOROALKYLIMIDAZOLE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DES RECEPTEUR MUSCARINIQUES M3 ET SEROTONIQUES 5-HT4 | SANOFI-SYNTHELABO (FR) | 2001-09-07 | — | — | WO | disclosed |
| WO-2000046220-A1 | TRIAZOLE AND TETRAZOLE DERIVATIVES, AND THEIR THERAPEUTIC USE | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | SIGMAR1 193/4885KDM4E 4716/4885ALDH1A1 1087/4885 |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | SIGMAR1 193/4885KDM4E 4716/4885ALDH1A1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.